Share with AI
ROSARITO BEACH, Mexico, March 16, 2026 – As U.S. lawmakers quietly accelerate discussions about research access and regulatory pathways for alternative therapies, the focus has begun to shift toward experienced clinicians who have been working with these treatments long before they entered the mainstream policy debate.
Among them is the leadership team at New Path Specialized Clinic, a medically supervised program that operates at the intersection of addiction recovery, trauma-related conditions, and neurological care.
This team has been serving patients since 2010, treating over 3,700 individuals, and is increasingly recognized as a key player in the evolving conversation about how responsible access to alternative treatments can look.
A Clinician-Led Approach with Decade-Long Experience
New Path's medical director, Dr. Carlos Abraham Silva, has been working with ibogaine since 2010 and has played a central role in developing the clinic's unique, medical model of care. Dr. Silva, an Internal Medicine Specialist, has a deep understanding of the complexities involved in treating addiction, trauma-related conditions, and neurological diseases like TBI and early Parkinson’s. This experience is critical as discussions continue on how to approach the responsible use of alternative therapies like ibogaine.
Dr. Silva emphasizes the clinic’s focus on medical supervision: "As legislation and policy start to catch up with the growing interest in alternative treatments, it is essential that we emphasize the importance of medical monitoring and responsible care. At New Path, we have been following this model for over a decade, with a structured and disciplined approach to ensure the safety and well-being of our patients."
The clinic’s model, according to Dr. Silva, revolves around rigorous screening, monitoring, and psychological support. Unlike some centers that have recently emerged, New Path emphasizes medical oversight rather than what it describes as a "retreat model," placing safety, monitoring, and long-term integration at the core of its operations.
A Power Partnership: Dr. Silva and Dr. Paula Cabrera
Dr. Silva is joined by his long-time clinical partner, Dr. Paula Cabrera, an integral part of the clinic’s leadership since 2012. The partnership between Dr. Silva and Dr. Cabrera provides stability in a field where continuity is often lacking. Their experience together forms a cornerstone of New Path’s approach to complex, high-risk patients.
“Together, we bring a shared clinical language and coordinated decision-making to our practice," said Dr. Cabrera. “Our work is built on trust—trust with each other as colleagues, and trust with our patients. This trust allows us to focus on providing the best possible care, no matter the complexity of the case.”
A Holistic Approach to Healing: Trauma-Informed Psychology
In addition to its medical leadership, New Path is known for its trauma-informed approach to psychology. Adria Luy, M.A., a psychologist at New Path, is focused on addressing the complex intersections of trauma and addiction. She emphasizes the importance of psychological integration, which she believes is crucial for patients with co-occurring mental health conditions such as C-PTSD.
“Spiritual or pharmacological experiences can be destabilizing without proper psychological support,” said Luy. “It’s not just about treatment—it’s about ensuring that patients have the tools and support they need to process and integrate those experiences in a way that supports long-term stability.”
A Unique Role for Gonzalo Armando Camacho, M.A.
Another key figure at New Path is Gonzalo Armando Camacho, M.A., a psychologist who serves as the clinic’s glue, ensuring integration across all disciplines. Camacho’s role extends beyond clinical care—he coordinates the medical, psychological, and nursing teams to ensure that New Path’s holistic approach is maintained throughout the patient journey.
"At New Path, we focus on whole-person care—body, mind, and soul,” Camacho said. “Our goal is to provide comprehensive support, recognizing that addiction and trauma are deeply intertwined with one’s overall well-being. We strive to ensure that no aspect of a patient’s recovery is overlooked.”
In addition to his leadership role, Camacho has played an instrumental part in pioneering early-stage work around Parkinson's support, an area gaining attention as policymakers recognize the broader potential for ibogaine beyond addiction.
Why Parkinson’s, TBI, and Trauma Are Capturing Policy Attention
The clinic’s innovative approach to treating trauma, addiction, and neurological conditions has garnered attention as state-level initiatives like Texas’ Senate Bill 2308 push for the inclusion of ibogaine in clinical trials for neurological disorders. As legislators look to expand research to include co-occurring mental health and neurological conditions, New Path’s work is more relevant than ever.
"The evidence is growing that alternative therapies like ibogaine could play a vital role in treating not only addiction but also conditions like Parkinson’s and TBI,” said Dr. Silva. “We have been at the forefront of this research for over a decade, and we are now seeing the fruits of that labor as policymakers begin to recognize the value of this work."
The Bottom Line: Policy is Moving, and Standards are Becoming the Story
While ibogaine remains a Schedule I controlled substance at the federal level in the U.S., the shifting political landscape is clear. States like Texas are leading the charge with funding for clinical trials, and other states are reviewing recommendations to integrate ibogaine into regulated frameworks.
The growing interest in alternative therapies has shifted the focus to clinics like New Path, which have established their credibility over years of medical oversight and patient care. As policymakers move toward regulated access, the emphasis will increasingly be on clinics that have demonstrated medical accountability, safety, and long-term integration.
Media Contact
+1-888-296-6664
Share this listing